Brewer ousts Lollini as Myrexis CEO
This article was originally published in Scrip
Myrexis has appointed Richard Brewer president and CEO. Mr Brewer replaces Robert Lollini, who served as interim president and CEO after Dr Adrian Hobden left the company in 2011, and took up the position on a permanent basis as recently as September 2011 (scripintelligence.com, 12 September 2011). Mr Brewer was formerly CEO of Scios. Mr Lollini will continue to serve on the board of directors during the transition period.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.